First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: A phase II study protocol OGSG 1602

A cytotoxic chemotherapeutic regimen is not routinely recommended for frail elderly patients with unresectable colorectal cancer (CRC) because of susceptibility to treatment. Panitumumab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR).